Targeted therapy of renal cell carcinoma
- VernacularTitle:肾细胞癌的靶向治疗
- Author:
Zhaoyan WANG
;
Erbing WANG
- Publication Type:Journal Article
- Keywords:
Renal cell carcinoma;
Targeted therapy
- From:
Cancer Research and Clinic
2006;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic renal cell carcinoma (RCC) is currently one of the treatment-resistant malignamcies. However, the elucidation of the molecular mechanisms underlying RCC development has led to the identification of promising targets for novel therapeutic agents. In Clinical studies, sunitinib and sorafenib have shown significant activity with manageable toxicity in the treatment of advanced or metastatic RCC. Both are oral agents which belong to a class of multitarget drugs called kinase inhibitor that inhibit the VEGF, platelet-derived growth factor(PDGF) and C-KIT receptor tyrosine kinase, which have been rapidly approved in the second-line and will soon be used as first-line therapy for RCC. Further studies with sunitinib or sorafenib as monotherapy and combination regimens in the treatment of RCC are warranted.
